Publications by authors named "Eliana Valentina Liardo"
Article Synopsis
- Chronic lymphocytic leukemia (CLL) is a type of cancer that affects certain white blood cells, which keep growing and don't die like they should.
- Pentoxifylline, a medication usually used for other problems, might help treat CLL by making cancer cells die off, which researchers studied by looking at blood samples from CLL patients and healthy people.
- After treating the CLL cells with Pentoxifylline, scientists found that the drug caused the cancer cells to die and worked through a specific pathway in the cells called NF-kB.
In this study we assessed the prognostic significance of absolute monocyte count and selected the best cut-off value at diagnosis in a large cohort of patients with diffuse large B-cell lymphoma. Data were retrieved for therapy-naïve patients with diffuse large B-cell lymphoma followed in Israel and Italy during 1993-2010. A final cohort of 1017 patients was analyzed with a median follow up of 48 months and a 5-year overall survival rate of 68%.
View Article and Find Full Text PDFIn this retrospective study we evaluated the prognostic impact of peripheral blood monocytosis in patients with T-cell non Hodgkin lymphomas with "aggressive-typically nodal presentation". In this dataset monocytes >0.8 × 10(9)/L had a strong and statistically significant negative impact on overall survival (OS).
View Article and Find Full Text PDFTherapy-related myeloid neoplasm in non-hodgkin lymphoma survivors.
Mediterr J Hematol Infect Dis
October 2012
Relatively little data on secondary cancers is available regarding patients treated for non-Hodgkin lymphoma (NHL), compared with those treated for Hodgkin lymphoma. Evolving treatment regimens have improved survival outcomes for NHL patients. As a result of this improvement, secondary malignancies are becoming an important issue in NHL survivors.
View Article and Find Full Text PDFThe effects of radiotherapy (RT) after chemotherapy in patients with diffuse large B-cell lymphoma (DLBCL) remain unclear; several trials have yielded conflicting results. This study examined the effect of RT after cyclophosphamide, doxorubicin, vincristine, and prednisone + rituximab (R-CHOP) treatment on event-free (EFS) and overall (OS) survival. Data from 216 patients with DLBCL who were enrolled in two clinical trials at Italian Lymphoma Study Group sites and were subjected to six R-CHOP cycles and involved-field radiotherapy (IFRT) were retrospectively analyzed.
View Article and Find Full Text PDF